Roivant Sciences shares jump after positive mid-stage trial results
Roivant Sciences shares rose 22% to $42.68 after the company disclosed positive results from a mid-stage trial evaluating its pulmonary hypertension treatment.
Shares of Roivant Sciences climbed after the company said it disclosed positive results from a mid-stage trial of its treatment for some instances of pulmonary hypertension, or high blood pressure in the arteries of the lungs and heart. 68.